[go: up one dir, main page]

EP4313101A4 - Peptide pour le traitement du cancer - Google Patents

Peptide pour le traitement du cancer

Info

Publication number
EP4313101A4
EP4313101A4 EP22782030.5A EP22782030A EP4313101A4 EP 4313101 A4 EP4313101 A4 EP 4313101A4 EP 22782030 A EP22782030 A EP 22782030A EP 4313101 A4 EP4313101 A4 EP 4313101A4
Authority
EP
European Patent Office
Prior art keywords
peptide
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22782030.5A
Other languages
German (de)
English (en)
Other versions
EP4313101A1 (fr
Inventor
Sergiy BORYSOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saint Leo University
Original Assignee
Saint Leo University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/215,845 external-priority patent/US12297295B2/en
Application filed by Saint Leo University filed Critical Saint Leo University
Publication of EP4313101A1 publication Critical patent/EP4313101A1/fr
Publication of EP4313101A4 publication Critical patent/EP4313101A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP22782030.5A 2021-03-29 2022-03-29 Peptide pour le traitement du cancer Pending EP4313101A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/215,845 US12297295B2 (en) 2019-09-27 2021-03-29 Peptide for treating cancer
PCT/US2022/022363 WO2022212389A1 (fr) 2021-03-29 2022-03-29 Peptide pour le traitement du cancer

Publications (2)

Publication Number Publication Date
EP4313101A1 EP4313101A1 (fr) 2024-02-07
EP4313101A4 true EP4313101A4 (fr) 2025-06-18

Family

ID=83456805

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22782030.5A Pending EP4313101A4 (fr) 2021-03-29 2022-03-29 Peptide pour le traitement du cancer

Country Status (3)

Country Link
EP (1) EP4313101A4 (fr)
CA (1) CA3206971A1 (fr)
WO (1) WO2022212389A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037091A2 (fr) * 1997-02-20 1998-08-27 Board Of Regents, The University Of Texas System Proteines modifiees de suppression des retinoblastomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228429D0 (en) * 2002-12-05 2003-01-08 Novartis Ag Organic compounds
EP3810793A4 (fr) * 2018-04-20 2021-11-03 Saint Leo University Peptide cyclique pour traiter le cancer
WO2021041953A1 (fr) * 2019-08-30 2021-03-04 The Regents Of The University Of California Méthodologies de criblage de surexpression de fragments de gènes et utilisations associées

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037091A2 (fr) * 1997-02-20 1998-08-27 Board Of Regents, The University Of Texas System Proteines modifiees de suppression des retinoblastomes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MASAKI OKUMURA ET AL: "A chemical method for investigating disulfide-coupled peptide and protein folding", FEBS JOURNAL, vol. 279, no. 13, 8 June 2012 (2012-06-08), pages 2283 - 2295, XP055134216, ISSN: 1742-464X, DOI: 10.1111/j.1742-4658.2012.08596.x *
See also references of WO2022212389A1 *

Also Published As

Publication number Publication date
CA3206971A1 (fr) 2022-10-06
WO2022212389A1 (fr) 2022-10-06
EP4313101A1 (fr) 2024-02-07

Similar Documents

Publication Publication Date Title
EP3930747A4 (fr) Association d'immunothérapies pour le traitement du cancer
EP4031543A4 (fr) Biaminoquinolines et nanoformulations pour le traitement du cancer
CA3264256A1 (fr) Composés pour le traitement du cancer
EP3962919A4 (fr) Composés pour traiter le cancer
EP3962524A4 (fr) Traitement du cancer
EP4330256A4 (fr) Pyrimidinylaminobenzènes pour le traitement du cancer du poumon
CA3262155A1 (fr) Composés pour le traitement du cancer
EP4313101A4 (fr) Peptide pour le traitement du cancer
EP4226945A4 (fr) Médicament pour le traitement du cancer
EP3969027A4 (fr) Polypeptides pour le traitement du cancer
HK40109687A (en) Methods for treating cancer
HK40116615A (zh) 治疗癌症用之药物组合
HK40095092A (en) Methods for treating cancer
HK40105935A (en) Pharmaceutical combinations for treating cancer
CA3274939A1 (fr) Méthodes de traitement du cancer exprimant dll3
CA3219579A1 (en) Methods for treating myc-amplified cancer
CA3271139A1 (fr) Méthodes de traitement du cancer
CA3270023A1 (fr) Méthodes de traitement du cancer
HK40087378A (en) Anti-ccr8 antibodies for treating cancer
HK40107047A (en) Therapeutic combination for treating cancer
HK40122790A (zh) 治疗癌症的方法和用途
HK40112852A (zh) 癌的治疗或预防用药物
HK40071284A (en) Methods for treating cancer
HK40078501A (en) Vector for cancer treatment
HK40108212A (en) Combination therapies for treating cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231023

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038000000

Ipc: C07K0014470000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/04 20060101ALI20250212BHEP

Ipc: A61K 38/08 20190101ALI20250212BHEP

Ipc: A61K 38/10 20060101ALI20250212BHEP

Ipc: A61K 38/00 20060101ALI20250212BHEP

Ipc: C07K 14/47 20060101AFI20250212BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/04 20060101ALI20250507BHEP

Ipc: A61K 38/08 20190101ALI20250507BHEP

Ipc: A61K 38/10 20060101ALI20250507BHEP

Ipc: A61K 38/00 20060101ALI20250507BHEP

Ipc: C07K 14/47 20060101AFI20250507BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20250516